display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone CheckMate 577

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons